Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF+DAC+BF vs G-CSF+DAC+BUCY in MDS/AML Allo-HSCT
NCT04713956Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2021
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of fludarabine in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.
02
Drugs
fludarabine
03
Conditions
myelodysplastic syndromes (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04713956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713956.